Clinical

CURRENT CLINICAL TRIAL ACTIVITIES*

(Official titles and [abbreviated titles])

1. Study of MABp1 in Patients with Advanced Cancers [Advanced Cancers]

2. Study of CA-18C3 in Subjects with Advanced Hematologic Malignancies [Leukemia]

3. Open Label, Randomized Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of an Anti-Inflammatory Therapeutic Antibody (CV-18C3) in Reducing Restenosis in Patients Undergoing Percutaneous Femoro-Popliteal Revascularization [Vascular Disease]

4. Open Label Study of the Safety, Pharmacokinetics, and Efficacy of a True Human™ Anti-Inflammatory Therapeutic Antibody (RA-18C3) in Subjects with Moderate to Severe Plaque Psoriasis [Psoriasis]

5. Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients with Type 2 Diabetes Mellitus [Type 2 Diabetes]

6. Open Label Study of the Safety, Pharmacokinetics, and Efficacy of a True Human™ Anti-Inflammatory Therapeutic Antibody (RA-18C3) in Subjects with Moderate to Severe Acne Vulgaris [Acne]

7. A Pivotal Phase III Study to Evaluate Overall Survival using MABp1 as a Monotherapy in Metastatic Colorectal Cancer Patients with Cachexia [Cancer]

*The MABp1 anti-IL-1α therapeutic antibody has been assigned different names depending on the clinical indication, such as MABp1, Xilonix™, CA-18C3, CV-18C3, RA-18C3, T2-18C3, etc. Each of these, however, contain the same True Human™ antibody MABp1.